S'abonner

Blood lipid levels associate with childhood asthma, airway obstruction, bronchial hyperresponsiveness, and aeroallergen sensitization - 07/01/16

Doi : 10.1016/j.jaci.2015.05.033 
Rebecca K. Vinding, MD a, b, Jakob Stokholm, MD, PhD a, b, Bo L.K. Chawes, MD, PhD a, Hans Bisgaard, MD, DMSc a,
a COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark 
b Department of Pediatrics, Naestved Hospital, Næstved, Denmark 

Corresponding author: Hans Bisgaard, MD, DMSc, COPSAC, Copenhagen Prospective Studies on Asthma in Childhood Herlev and Gentofte Hospital, University of Copenhagen Ledreborg Allé 34 DK-2820 Gentofte, Denmark.

Abstract

Background

Studies of children's blood lipid profiles in relation to asthma are few, and the results are ambiguous.

Objective

We sought to examine whether the lipid profile is associated with concurrent asthma, altered lung function, and allergic sensitization in children.

Methods

High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were measured at ages 5 to 7 years in the Copenhagen Prospective Studies on Asthma in Childhood2000 at-risk birth cohort. Asthma and allergic rhinitis were diagnosed based on predefined algorithms at age 7 years along with assessments of lung function, bronchial responsiveness, fraction of exhaled nitric oxide (Feno), and allergic sensitization. Associations between lipid levels and clinical outcomes were adjusted for sex, passive smoking, and body mass index.

Results

High levels of low-density lipoprotein cholesterol were associated with concurrent asthma (adjusted odds ratio [aOR], 1.93; 95% CI, 1.06-3.55; P = .03) and airway obstruction: 50% of forced expiratory flow (aβ coefficient, −0.13 L/s; 95% CI, −0.24 to −0.03 L/s; P = .01) and specific airway resistance (aβ coefficient, 0.06 kPa/s; 95% CI, 0.00-0.11 kPa/s; P = .05). High levels of high-density lipoprotein cholesterol were associated with improved specific airway resistance (aβ coefficient, −0.11 kPa/s; 95% CI, −0.21 to −0.02; P = .02), decreased bronchial responsiveness (aβ coefficient, 0.53 log-μmol; 95% CI, 0.00-1.60 log-μmol; P = .05), decreased risk of aeroallergen sensitization (aOR, 0.27; 95% CI, 0.01-0.70; P = .01), and a trend of reduced Feno levels (aβ coefficient, −0.22 log-ppb; 95% CI, −0.50 to 0.01 log-ppb; P = .06). High triglyceride levels were associated with aeroallergen sensitization (aOR, 2.01; 95% CI, 1.14-3.56; P = .02) and a trend of increased Feno levels (aβ coefficient, 0.14 log-ppb; 95% CI, −0.02 to 0.30 log-ppb; P = .08).

Conclusion

The blood lipid profile is associated with asthma, airway obstruction, bronchial responsiveness, and aeroallergen sensitization in 7-year-old children. These findings suggest that asthma and allergy are systemic disorders with commonalities with other chronic inflammatory disorders.

Le texte complet de cet article est disponible en PDF.

Key words : Blood lipids, asthma, child, respiratory function tests, inflammation

Abbreviations used : aOR, BMI, COPSAC2000, Feno, HDL-C, LDL-C, PC, PCA, sRaw


Plan


 COPSAC is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation (R16-A1694), The Ministry of Health (903516), Danish Council for Strategic Research, and Capital Region Research Foundation have provided core support for COPSAC. B.L.K.C. was supported by the Thrasher Research Award. The funding agencies did not have any influence on study design, data collection and analysis, decision to publish or preparation of the manuscript. Thermo Fisher Scientific Inc sponsored the IgE analyses. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 137 - N° 1

P. 68 - janvier 2016 Retour au numéro
Article précédent Article précédent
  • Small RNA profiling reveals deregulated phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/Akt pathway in bronchial smooth muscle cells from asthmatic patients
  • Elena Alexandrova, Nicola Miglino, Adnan Hashim, Giovanni Nassa, Claudia Stellato, Michael Tamm, Florent Baty, Martin Brutsche, Alessandro Weisz, Pieter Borger
| Article suivant Article suivant
  • Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia
  • Steven G. Smith, Ruchong Chen, Melanie Kjarsgaard, Chynna Huang, John-Paul Oliveria, Paul M. O'Byrne, Gail M. Gauvreau, Louis-Philippe Boulet, Catherine Lemiere, James Martin, Parameswaran Nair, Roma Sehmi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.